Peter Lynch fit · Growth at a reasonable price (GARP)
Is Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) a Peter Lynch Stock?
Strong GARP candidate — growth at a reasonable price.
72/100
BAction Lynch probable
5/6 critères validés
Les critères de Peter Lynch, appliqués à AMRX
PEG ≤ 1.0
clé—
EPS CAGR ≥ 15%
clé37.4%
Revenue CAGR ≥ 10%
37.6%
Net margin > 0
0.2%
Comment AMRX se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$4.21B
PER (TTM)
-
ROIC (TTM)
9.19%
Marge brute
36.76%
Questions fréquentes
What is AMRX's Peter Lynch fit score?
AMRX scores 72/100 on our Peter Lynch fit engine — grade B. Strong GARP candidate — growth at a reasonable price.
Does Peter Lynch actually own AMRX?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends AMRX.
How often is this score updated?
AMRX's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande AMRX personnellement.